Detection and Monitoring of Viral Infections via Wearable Devices and Biometric Data -Supplemental Information

Craig J. Goergen,¹ MacKenzie J. Tweardy,² Steven R. Steinhubl,^{2,3} Stephan W. Wegerich,² Karnika Singh,⁴ Rebecca J. Mieloszyk,⁵ and Jessilyn Dunn⁴

¹Weldon School of Biomedical Engineering, Purdue University, West Lafayette, USA, 47907; email: cgoergen@purdue.edu

²physIQ Inc., Chicago, USA, 60606

³Scripps Research Translational Institute, LaJolla, USA 92037

⁴Department of Biomedical Engineering, Duke University, Durham, USA, 27708
⁵Microsoft Research, Redmond, USA, 98052

Annu. Rev. Biomed. Eng. 2022. AA:1–9

 $\label{eq:https://doi.org/10.1146/annurev-bioeng-103020-040136} ttps://doi.org/10.1146/annurev-bioeng-103020-040136$

Copyright © 2022 by Annual Reviews. All rights reserved

Contents

L.	SUPPLEMENTAL INFORMATION	2
	1.1. Reproducibility and Replicability	2
	1.2. Data Privacy	2
	1.3. Population Data for Viral Illness Epidemiology	4
	1.4. BioMeT Data for Individual Diagnosis and Prognosis	5

1. SUPPLEMENTAL INFORMATION

1.1. Reproducibility and Replicability

There are several online platforms aimed at connecting researchers to encourage collaboration and resource sharing in the field of digital medicine. For instance, the Digital Biomarker Discovery Pipeline provides code for wearable data processing and digital biomarker discovery (1). The Digital Health Data Repository (DHDR) curates datasets in the digital health space and includes sample data for use with the DBDP. The aim of the DBDP is to provide all resources for digital biomarker discovery to facilitate collaborations and transparency for wearable data analysis (1). There have been increasing partnerships between research groups and commercial manufacturers to explore the utility of BioMeTs for detecting stress, ILI, and COVID-19 (2). This allows researchers access to a much larger dataset and for manufacturers to extend device utility. Increasing transparency and openness by making data and code openly available is increasingly being adopted to improve replicability. The DBDP is the first comprehensive platform for open-source, end-to-end digital biomarker development (3). This will enable researchers to verify published results and to conduct alternative analyses, thereby also extending the utility of collected data. Several efforts like the All of Us Research Program, the DHDR, the UCI Machine Learning Repository, Physionet, and MHEALTH make datasets available for use by other researchers.

1.2. Data Privacy

There have been several efforts to ensure security of patient data from biometric monitoring technologies (BioMeTs) (4). However, considerable gaps exist in the protection of medical and personal health information which will have to be addressed as BioMeTs become more widely used in healthcare. Concerns regarding the use of wearables and sensors in healthcare include ethical, legal, data security, infrastructure, and regulatory risks (5). Lack of technical expertise required to safeguard personal device data can pose a data security risk. Since most research studies require individuals to operate their consumer BioMeTs themselves, these studies need to ensure that users understand the best practices to safeguard their data.

Transmission between BioMeTs and data storage are both prone to security threats. Rigorous measures need to be put in place to ensure data security at all levels, especially due to the current lack of governance and guidelines safeguarding BioMeT data collection. The Health Insurance Portability and Accountability Act (HIPAA) was put in place to ensure protection of health information, and the HIPAA security rule requires specific protections to safeguard electronic health. Similar guidelines need to be established for secure storage and sharing of information collected from BioMeTs. Standard guidelines would ensure compliance from all research groups and improve security measures for data storage. Secure data storage and sharing standards for digital health data are essential to advance the use of BioMeT-informed decisions in clinical care.

The fact that BioMeTs collect a host of personal data pertaining to location, health status, and lifestyle raises questions regarding data privacy (6). Anonymization, or techniques to protect individual privacy in databases storing personal information by deleting identifiable information such as names, addresses, telephone numbers, and social security numbers, are usually employed to safeguard user information. The digital health field is still in the process of defining methods to anonymize data and to understand whether true de-identification without the possibility of re-identification is a realistic goal (7, 8). To preserve trust from consumers, patients, and research participants, secure data storage and sharing standards for digital health data are essential. More research is needed to determine if current de-identification practices are adequate or whether novel solutions are required to protect user identities.

Ensuring research study participant understanding of privacy concerns is necessary and must be conveyed through informed consent. Although BioMeTs might collect personal data only after users agree and sign consent forms, most users provide consent without a thorough understanding of what the legal agreements entail. Employing BioMeTs for measuring outcomes in clinical studies must involve a complete user understanding of associated risks and benefits. An informed consent ensures that the participants comprehend all the information correctly and can make an autonomous decision. Concerningly, there are still unresolved legal issues to be tackled in this field. The extent of coverage of Certificates of Confidentiality for data collected from personal digital devices is an example. Appropriate efforts must be undertaken to provide all the information required to make an informed decision by employing tools like audio-visual aids, assessment of patient comprehension, extended discussions between participants and the research team, and study brochures (9). In the field of genetics, genetic counselors help patients navigate the consent process by providing information and offering guidance. Similarly, a digital medicine counselor who possesses expertise in digital data could guide individuals through the potential benefits and risks of contributing BioMeT-collected data for research purposes. This would also boost public confidence in research studies by helping participants navigate all their concerns with the right information. Enabling participants to understand the potential risk of loss of privacy with such studies is an important part of ensuring truly informed consent.

1.3. Population Data for Viral Illness Epidemiology

Viral Features BioMeT(s) **Population** Key Findings Illness Size Analyzed Radin 60,473 Influenza HR, Fitbit Individuals with a Fitbit weekly mean HR Sleep, Analysis $0.5 ext{ SD}^1$ above Activity (10)their yearly average and weekly activity 1.0 SD less than their average correlated with local CDC^2 ILI^3 rates The weekly pro-Scripps' Influenza HR, Fitbit 47,249 Fitbit Sleep portion of users Study (11) with anomalous Fitbit data significantly improved models using CDC ILI data from three weeks prior to predict current ILI at the state level in the USCorona COVID-538,010 HR, Ac-Multiple $\operatorname{BioMeTs}$ data Data Do-19tivity wrist correlated with BioMeTs nation App local COVID-19 (12)case counts in Germany

Supplemental Table 1: Population-level viral illness information via BioMeTs data - real world evidence

 $^2 \mathrm{Centers}$ for Disease Control and Prevention $^3 \mathrm{Influenza-like}$ illness

Influenza-like illn

4 Goergen et al.

¹Standard deviation

Huami	COVID-	HR,	Huami	1.3 million	Physiological
	19	· ·	BioMeTs	1.5 mmon	
Users (13)	19	Sleep	BIOMETS		anomalies, de-
					fined as a resting
					HR 1.5 SD above
					a person's normal
					or sleep longer
					than 0.5 SD
					below normal,
					correlated with
					COVID-19 case
					counts in Chinese
					cities
Twenty	COVID-	HR,	Oura Ring	113,000	Stricter lock-
Country	19 (effect	Sleep			downs were
Lockdown	of lock-				associated with
Impact in	downs)				delayed mid-sleep
Oura Ring					times, with de-
Users (14)					creased variability
					and resting HR

1.4. BioMeT Data for Individual Diagnosis and Prognosis

Supplemental Table 2: Individual-level diagnosis and/or prognosis of viral illness via BioMeT data

	Viral Illness	Features Ana- lyzed	BioMeT(s)	Population Size (Number of Cases)	Key Findings
Evidation	Influenza	HR,	Multiple	9,495 with	Changes in sleep,
Achieve-		sleep,	wrist	data	activity and HR
ment App		activity	BioMeTs		correlated with
(15)					self-reported
					symptoms consis-
					tent with ILI.
TemPredict	COVID-	Skin	Oura Ring	50(50)	Individual eleva-
(16)	19	temp.,			tions in peripheral
		HR,			temperature cor-
		RR,			relate with self-
		HRV			reported fever.

	COLID	IID	T1.1.1.	F 262 (22)	M & COUTE 12
Stanford	COVID-	HR,	Fitbit, Ap-	5,262 (32)	Most COVID-19
COVID-19	19	sleep,	ple Watch,		cases had changes
Wearables		activity	Garmin,		in their HR,
Study (17)			and other		steps or sleep.
					Two-thirds could
					have potentially
					been detected
					pre-symptoms
					onset.
Fitbit	COVID-	HR,	Fitbit	187,573	HR and RR are
Study (18)	19	activity,		(2,745)	typically elevated,
		RR,			and HRV reduced
		HRV,			in those with in-
		sleep			fection and can
					help in its predic-
					tion.
Stanford	COVID-	HR	Fitbit, Ap-	2,112 with	Alerts were gen-
Real-Time	19		ple Watch,	data (68)	erated a median
Alerting			Garmin		of 3 days prior
Study (19)			and other		to symptoms in
					the majority of
					COVID-19 cases,
					but also other in-
					fections and non-
					infection events.
DETECT	COVID-	RHR,	Data from	30,529(54)	BioMeT data
(20)	19 &	sleep,	Fitbit and		can signifi-
	other	activity	any Apple		cantly improve
	viral res-		HealthKit-		symptom-only
	piratory		or Google		based models to
	infections		Fit-		predict COVID-
			connected		19 positivity.
			BioMeT		
Whoop	COVID-	RR,	WHOOP	271 (81)	Changes in sleep-
System	19	RHR,			ing RR identified
(21)		HRV			a minority of
					COVID-19 pos-
					itive cases in 2
					days prior to
					symptom onset.
System	COVID-	RHR,	connected BioMeT	271 (81)	19 positivity. Changes in sleep- ing RR identified a minority of COVID-19 pos- itive cases in 2 days prior to

6 Goergen et al.

	COMP	DIID	D:/1:/	6.000	
Evidation	COVID-	RHR,	Fitbit	6,926	BioMeT data
(22)	19,	activity,		(1,311 In-	showed similar
	Influenza	sleep		fluenza, 41	magnitudes in
				COVID-19	daily changes of
				with data)	steps and HR for
					both influenza
					and COVID-19
					cohorts
Warrior	COVID-	HRV	Apple	297(48)	HRV metrics
Watch	19		Watch		can help iden-
Study (23)					tify individuals
					with COVID-
					19 and related
					symptoms.
CovIdentify	COVID-	RHR,	All Apple	7501 (80	Increased RHR
(24)	19,	sleep,	HealthKit-	COVID-	and decreased
	Influenza	activity	connected	19; 116	Steps 3-5 days
			BioMeTs	Influenza)	prior to test.
					Reported demo-
					graphic imbal-
					ances in BYOD
					studies.
DeCODe	COVID-	Multiple	VitalPatch	Plans for	All participants
(25, 26)	19	features		1600 with	COVID-19 pos-
				400 in	itive. Wearable
				phase 1	patch data and
				and 1200	analytic en-
				in phase 2	gine to identify
				*	early signs of
					decompensa-
					tion requiring
					hospitalization.
	1	1			L *

LITERATURE CITED

- 1. Digital health data repository (dhdr), jul 2021.
- 2. Can your garmin detect coronavirus?, April 2020. Publication Title: Garmin Blog.
- B. Bent, K. Wang, E. Grzesiak, C. Jiang, Y. Qi, Y. Jiang, P. Cho, K. Zingler, F.I. Ogbeide, A. Zhao, R. Runge, I. Sim, and J.P. Dunn. The digital biomarker discovery pipeline: An opensource software platform for the development of digital biomarkers using mhealth and wearables data. *Journal of Clinical and Translational Science*, 5(1), 2021.
- B. Woods, A. Coravos, and Joshua D. Corman. The case for a hippocratic oath for connected medical devices. *Journal of medical Internet research*, 21(3):e12568, 2019.
- E.S. Izmailova, J.A. Wagner, and E.D. Perakslis. Wearable devices in clinical trials: Hype and hypothesis. *Clinical Pharmacology and Therapeutics*, 104(1):42–52, jul 2018.
- 6. T. Jourdan, A. Boutet, A. Bahi, and C. Frindel. Privacy-preserving iot framework for activity recognition in personal healthcare monitoring. *ACM Transactions on Computing for*

www.annualreviews.org • Viral Infection Detection via Wearable Devices 7

Healthcare, 2(1):3:1–3:22, December 2021.

- F. Lobelo, H. M. Kelli, S. C. Tejedor, M. Pratt, M. V. McConnell, S. S. Martin, and G. J. Welk. The wild wild west: A framework to integrate mhealth software applications and wearables to support physical activity assessment, counseling and interventions for cardiovascular disease risk reduction. *Progress in Cardiovascular Diseases*, 58(6):584–594, jun 2016.
- L. Na, C. Yang, C. Lo, F. Zhao, Y. Fukuoka, and A. Aswani. Feasibility of reidentifying individuals in large national physical activity data sets from which protected health information has been removed with use of machine learning. *JAMA Network Open*, 1(8):e186040–e186040, dec 2018.
- R.A. Kadam. Informed consent process: A step further towards making it meaningful! Perspectives in clinical research, 8(3):107, 2017.
- J.M. Radin, G. Queer, and S.R. Steinhubl. Can Wearable Sensors Detect Influenza Epidemics? Correlation of Anomalous Fitbit Data with Influenza Surveillance Data. *Emerging Infectious Diseases*, 24(9):47, 2018.
- J. M. Radin, N. E. Wineinger, E. J. Topol, and S. R. Steinhubl. Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the usa: a populationbased study. *Lancet Digit Health*, 2(2):e85–e93, 2020.
- 12. Corona-Datenspende: https://corona-datenspende.de/science/en/, 2020.
- G. Zhu, J. Li, Z. Meng, Y. Yu, Y. Li, X. Tang, Y. Dong, G. Sun, R. Zhou, H. Wang, K. Wang, and W. Huang. Learning from Large-Scale Wearable Device Data for Predicting Epidemics Trend of COVID-19. *Discrete Dynamics in Nature and Society*, 2020, 2020.
- J.L. Ong, T. Lau, M. Karsikas, H. Kinnunen, and M. Chee. A longitudinal analysis of COVID-19 lockdown stringency on sleep and resting heart rate measures across 20 countries. *Scientific Reports 2021 11:1*, 11(1):1–11, jul 2021.
- B. Bradshaw, K.J. Konty, E. Ramirez, W. Lee, A. Signorini, and L. Foschini. Influenza Surveillance Using Wearable Mobile Health Devices. *Online Journal of Public Health Informatics*, 11(1), may 2019.
- B.L. Smarr, K. Aschbacher, S.M. Fisher, A. Chowdhary, S. Dilchert, K. Puldon, A. Rao, F.M. Hecht, and A.E. Mason. Feasibility of continuous fever monitoring using wearable devices. *Scientific Reports 2020 10:1*, 10(1):1–11, dec 2020.
- T. Mishra, M. Wang, A.A. Metwally, G.K. Bogu, A.W. Brooks, A. Bahmani, A. Alavi, A. Celli, E. Higgs, O. Dagan-Rosenfeld, B. Fay, S. Kirkpatrick, R. Kellogg, M. Gibson, T. Wang, E.M. Hunting, P. Mamic, A.B. Ganz, B. Rolnik, X. Li, and M.P. Snyder. Pre-symptomatic detection of COVID-19 from smartwatch data. *Nature Biomedical Engineering*, 4(12):1208–1220, nov 2020.
- A. Natarajan, H. Su, and C. Heneghan. Assessment of physiological signs associated with COVID-19 measured using wearable devices. *npj Digital Medicine 2020 3:1*, 3(1):1–8, nov 2020.
- 19. Arash Alavi, Gireesh K. Bogu, Meng Wang, Ekanath Srihari Rangan, Andrew W. Brooks, Qiwen Wang, Emily Higgs, Alessandra Celli, Tejaswini Mishra, Ahmed A. Metwally, Kexin Cha, Peter Knowles, Amir A. Alavi, Rajat Bhasin, Shrinivas Panchamukhi, Diego Celis, Tagore Aditya, Alexander Honkala, Benjamin Rolnik, Erika Hunting, Orit Dagan-Rosenfeld, Arshdeep Chauhan, Jessi W. Li, Caroline Bejikian, Vandhana Krishnan, Lettie McGuire, Xiao Li, Amir Bahmani, and Michael P. Snyder. Real-time alerting system for covid-19 and other stress events using wearable data. *Nature Medicine*, nov 2021.
- G. Quer, J.M. Radin, M. Gadaleta, K. Baca-Motes, L. Ariniello, E. Ramos, V. Kheterpal, E.J. Topol, and S.R. Steinhubl. Wearable sensor data and self-reported symptoms for COVID-19 detection. *Nature Medicine 2020 27:1*, 27(1):73–77, oct 2020.
- D.J. Miller, J.V. Capodilupo, M. Lastella, C. Sargent, G.D. Roach, V.H. Lee, and E.R. Capodilupo. Analyzing changes in respiratory rate to predict the risk of COVID-19 infection. *PLOS ONE*, 15(12):e0243693, dec 2020.
- 8 Goergen et al.

- 22. A. Shapiro, N. Marinsek, I. Clay, B. Bradshaw, E. Ramirez, J. Min, A. Trister, Y. Wang, T. Althoff, and L. Foschini. Characterizing COVID-19 and Influenza Illnesses in the Real World via Person-Generated Health Data. *Patterns*, 2(1), jan 2021.
- 23. R.P. Hirten, M. Danieletto, Lewis Tomalin, K.H. Choi, M. Zweig, E. Golden, S. Kaur, D. Helmus, A. Biello, R. Pyzik, A. Charney, R. Miotto, B.S. Glicksberg, M. Levin, I. Nabeel, J. Aberg, D. Reich, D. Charney, E.P. Bottinger, L. Keefer, M. Suarez-Farinas, G.N. Nadkarni, and Z.A. Fayad. Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study. *Journal of Medical Internet Research*, 23(2), feb 2021.
- 24. P.J. Cho, J.J. Yi, E. Ho, Y.H. Dinh, A. Patil, L. Martin, G. Singh, M.H. Shandhi, B. Bent, G.S. Ginsburg, M. Smuck, C. Woods, R. Shaw, and J.P. Dunn. The demographic improvement guideline to reduce bias resulting from bring-your-own-device study design. *JMIR mHealth and uHealth*, Epub ahead of print, dec 2021. doi: 10.2196/29510.
- 25. K. Larimer, S. Wegerich, J. Splan, D. Chestek, H. Prendergast, and T. Van den Hoek. Personalized Analytics and a Wearable Biosensor Platform for Early Detection of COVID-19 Decompensation (DeCODe): Protocol for the Development of the COVID-19 Decompensation Index. *JMIR Research Protocols*, 10(5), may 2021.
- D.M. Richards, M.J. Tweardy, S.R. Steinhubl, D.W. Chestek, T.L.V. Hoek, K.A. Larimer, and S.W. Wegerich. Wearable sensor derived decompensation index for continuous remote monitoring of COVID-19 diagnosed patients. *NPJ Digital Medicine*, 4(1):155, nov 2021.